Financhill
Sell
50

MRUS Quote, Financials, Valuation and Earnings

Last price:
$53.33
Seasonality move :
2.25%
Day range:
$52.25 - $53.69
52-week range:
$33.19 - $62.98
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
64.40x
P/B ratio:
6.11x
Volume:
583.2K
Avg. volume:
1.6M
1-year change:
-3.29%
Market cap:
$3.6B
Revenue:
$36.1M
EPS (TTM):
-$4.08

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
MRUS
Merus NV
$9.9M -$1.15 41.37% -39.39% $90.20
ARGX
argenx SE
$897.7M $2.94 85.28% 502.3% $771.22
PHAR
Pharming Group
$82.5M -$0.01 11.82% -25% $30.33
PHVS
Pharvaris NV
-- -$0.89 -- -46.46% $33.83
PRQR
ProQR Therapeutics NV
$5M -$0.17 -26.75% -63.67% $8.88
QURE
uniQure NV
$5.9M -$0.90 -49.23% -25.47% $36.24
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
MRUS
Merus NV
$52.66 $90.20 $3.6B -- $0.00 0% 64.40x
ARGX
argenx SE
$542.47 $771.22 $33.1B 33.22x $0.00 0% 13.54x
PHAR
Pharming Group
$10.71 $30.33 $732.5M -- $0.00 0% 2.70x
PHVS
Pharvaris NV
$17.25 $33.83 $940M -- $0.00 0% --
PRQR
ProQR Therapeutics NV
$2.01 $8.88 $211.7M -- $0.00 0% 9.08x
QURE
uniQure NV
$13.99 $36.24 $765.9M -- $0.00 0% 34.51x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
MRUS
Merus NV
-- 0.551 -- 5.34x
ARGX
argenx SE
-- -0.134 -- 6.40x
PHAR
Pharming Group
29.23% -0.909 15.42% 2.00x
PHVS
Pharvaris NV
-- -0.824 -- --
PRQR
ProQR Therapeutics NV
5.57% 1.651 3.6% 4.01x
QURE
uniQure NV
60.5% -5.009 8.9% 11.33x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
MRUS
Merus NV
-- -$75.7M -45.56% -45.56% -285.94% -$96.6M
ARGX
argenx SE
$709.9M $141.2M 18.03% 21.33% 25.74% -$147M
PHAR
Pharming Group
$70.8M -$7.4M -4.46% -6.48% -8.46% -$56K
PHVS
Pharvaris NV
-- -$44.4M -- -- -- -$40.7M
PRQR
ProQR Therapeutics NV
-- -$11.4M -53.43% -58.1% -239.35% -$16.9M
QURE
uniQure NV
$1.4M -$39.3M -158.75% -333.08% -1788.9% -$44.2M

Merus NV vs. Competitors

  • Which has Higher Returns MRUS or ARGX?

    argenx SE has a net margin of -364.22% compared to Merus NV's net margin of 21.43%. Merus NV's return on equity of -45.56% beat argenx SE's return on equity of 21.33%.

    Company Gross Margin Earnings Per Share Invested Capital
    MRUS
    Merus NV
    -- -$1.40 $596.1M
    ARGX
    argenx SE
    89.78% $2.58 $5.5B
  • What do Analysts Say About MRUS or ARGX?

    Merus NV has a consensus price target of $90.20, signalling upside risk potential of 71.29%. On the other hand argenx SE has an analysts' consensus of $771.22 which suggests that it could grow by 42.17%. Given that Merus NV has higher upside potential than argenx SE, analysts believe Merus NV is more attractive than argenx SE.

    Company Buy Ratings Hold Ratings Sell Ratings
    MRUS
    Merus NV
    13 0 0
    ARGX
    argenx SE
    15 1 0
  • Is MRUS or ARGX More Risky?

    Merus NV has a beta of 0.997, which suggesting that the stock is 0.282% less volatile than S&P 500. In comparison argenx SE has a beta of 0.369, suggesting its less volatile than the S&P 500 by 63.097%.

  • Which is a Better Dividend Stock MRUS or ARGX?

    Merus NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. argenx SE offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Merus NV pays -- of its earnings as a dividend. argenx SE pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios MRUS or ARGX?

    Merus NV quarterly revenues are $26.5M, which are smaller than argenx SE quarterly revenues of $790.7M. Merus NV's net income of -$96.5M is lower than argenx SE's net income of $169.5M. Notably, Merus NV's price-to-earnings ratio is -- while argenx SE's PE ratio is 33.22x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Merus NV is 64.40x versus 13.54x for argenx SE. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    MRUS
    Merus NV
    64.40x -- $26.5M -$96.5M
    ARGX
    argenx SE
    13.54x 33.22x $790.7M $169.5M
  • Which has Higher Returns MRUS or PHAR?

    Pharming Group has a net margin of -364.22% compared to Merus NV's net margin of -18.61%. Merus NV's return on equity of -45.56% beat Pharming Group's return on equity of -6.48%.

    Company Gross Margin Earnings Per Share Invested Capital
    MRUS
    Merus NV
    -- -$1.40 $596.1M
    PHAR
    Pharming Group
    89.48% -$0.22 $303.7M
  • What do Analysts Say About MRUS or PHAR?

    Merus NV has a consensus price target of $90.20, signalling upside risk potential of 71.29%. On the other hand Pharming Group has an analysts' consensus of $30.33 which suggests that it could grow by 183.22%. Given that Pharming Group has higher upside potential than Merus NV, analysts believe Pharming Group is more attractive than Merus NV.

    Company Buy Ratings Hold Ratings Sell Ratings
    MRUS
    Merus NV
    13 0 0
    PHAR
    Pharming Group
    2 0 0
  • Is MRUS or PHAR More Risky?

    Merus NV has a beta of 0.997, which suggesting that the stock is 0.282% less volatile than S&P 500. In comparison Pharming Group has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

  • Which is a Better Dividend Stock MRUS or PHAR?

    Merus NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pharming Group offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Merus NV pays -- of its earnings as a dividend. Pharming Group pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios MRUS or PHAR?

    Merus NV quarterly revenues are $26.5M, which are smaller than Pharming Group quarterly revenues of $79.1M. Merus NV's net income of -$96.5M is lower than Pharming Group's net income of -$14.7M. Notably, Merus NV's price-to-earnings ratio is -- while Pharming Group's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Merus NV is 64.40x versus 2.70x for Pharming Group. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    MRUS
    Merus NV
    64.40x -- $26.5M -$96.5M
    PHAR
    Pharming Group
    2.70x -- $79.1M -$14.7M
  • Which has Higher Returns MRUS or PHVS?

    Pharvaris NV has a net margin of -364.22% compared to Merus NV's net margin of --. Merus NV's return on equity of -45.56% beat Pharvaris NV's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    MRUS
    Merus NV
    -- -$1.40 $596.1M
    PHVS
    Pharvaris NV
    -- -$0.89 --
  • What do Analysts Say About MRUS or PHVS?

    Merus NV has a consensus price target of $90.20, signalling upside risk potential of 71.29%. On the other hand Pharvaris NV has an analysts' consensus of $33.83 which suggests that it could grow by 96.14%. Given that Pharvaris NV has higher upside potential than Merus NV, analysts believe Pharvaris NV is more attractive than Merus NV.

    Company Buy Ratings Hold Ratings Sell Ratings
    MRUS
    Merus NV
    13 0 0
    PHVS
    Pharvaris NV
    7 0 0
  • Is MRUS or PHVS More Risky?

    Merus NV has a beta of 0.997, which suggesting that the stock is 0.282% less volatile than S&P 500. In comparison Pharvaris NV has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

  • Which is a Better Dividend Stock MRUS or PHVS?

    Merus NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pharvaris NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Merus NV pays -- of its earnings as a dividend. Pharvaris NV pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios MRUS or PHVS?

    Merus NV quarterly revenues are $26.5M, which are larger than Pharvaris NV quarterly revenues of --. Merus NV's net income of -$96.5M is lower than Pharvaris NV's net income of -$48.8M. Notably, Merus NV's price-to-earnings ratio is -- while Pharvaris NV's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Merus NV is 64.40x versus -- for Pharvaris NV. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    MRUS
    Merus NV
    64.40x -- $26.5M -$96.5M
    PHVS
    Pharvaris NV
    -- -- -- -$48.8M
  • Which has Higher Returns MRUS or PRQR?

    ProQR Therapeutics NV has a net margin of -364.22% compared to Merus NV's net margin of -223.04%. Merus NV's return on equity of -45.56% beat ProQR Therapeutics NV's return on equity of -58.1%.

    Company Gross Margin Earnings Per Share Invested Capital
    MRUS
    Merus NV
    -- -$1.40 $596.1M
    PRQR
    ProQR Therapeutics NV
    -- -$0.11 $90.5M
  • What do Analysts Say About MRUS or PRQR?

    Merus NV has a consensus price target of $90.20, signalling upside risk potential of 71.29%. On the other hand ProQR Therapeutics NV has an analysts' consensus of $8.88 which suggests that it could grow by 341.54%. Given that ProQR Therapeutics NV has higher upside potential than Merus NV, analysts believe ProQR Therapeutics NV is more attractive than Merus NV.

    Company Buy Ratings Hold Ratings Sell Ratings
    MRUS
    Merus NV
    13 0 0
    PRQR
    ProQR Therapeutics NV
    6 0 0
  • Is MRUS or PRQR More Risky?

    Merus NV has a beta of 0.997, which suggesting that the stock is 0.282% less volatile than S&P 500. In comparison ProQR Therapeutics NV has a beta of 0.365, suggesting its less volatile than the S&P 500 by 63.535%.

  • Which is a Better Dividend Stock MRUS or PRQR?

    Merus NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ProQR Therapeutics NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Merus NV pays -- of its earnings as a dividend. ProQR Therapeutics NV pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios MRUS or PRQR?

    Merus NV quarterly revenues are $26.5M, which are larger than ProQR Therapeutics NV quarterly revenues of $4.8M. Merus NV's net income of -$96.5M is lower than ProQR Therapeutics NV's net income of -$10.6M. Notably, Merus NV's price-to-earnings ratio is -- while ProQR Therapeutics NV's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Merus NV is 64.40x versus 9.08x for ProQR Therapeutics NV. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    MRUS
    Merus NV
    64.40x -- $26.5M -$96.5M
    PRQR
    ProQR Therapeutics NV
    9.08x -- $4.8M -$10.6M
  • Which has Higher Returns MRUS or QURE?

    uniQure NV has a net margin of -364.22% compared to Merus NV's net margin of -2784.75%. Merus NV's return on equity of -45.56% beat uniQure NV's return on equity of -333.08%.

    Company Gross Margin Earnings Per Share Invested Capital
    MRUS
    Merus NV
    -- -$1.40 $596.1M
    QURE
    uniQure NV
    87.43% -$0.82 $85.3M
  • What do Analysts Say About MRUS or QURE?

    Merus NV has a consensus price target of $90.20, signalling upside risk potential of 71.29%. On the other hand uniQure NV has an analysts' consensus of $36.24 which suggests that it could grow by 159.05%. Given that uniQure NV has higher upside potential than Merus NV, analysts believe uniQure NV is more attractive than Merus NV.

    Company Buy Ratings Hold Ratings Sell Ratings
    MRUS
    Merus NV
    13 0 0
    QURE
    uniQure NV
    9 2 0
  • Is MRUS or QURE More Risky?

    Merus NV has a beta of 0.997, which suggesting that the stock is 0.282% less volatile than S&P 500. In comparison uniQure NV has a beta of 0.077, suggesting its less volatile than the S&P 500 by 92.298%.

  • Which is a Better Dividend Stock MRUS or QURE?

    Merus NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. uniQure NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Merus NV pays -- of its earnings as a dividend. uniQure NV pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios MRUS or QURE?

    Merus NV quarterly revenues are $26.5M, which are larger than uniQure NV quarterly revenues of $1.6M. Merus NV's net income of -$96.5M is lower than uniQure NV's net income of -$43.6M. Notably, Merus NV's price-to-earnings ratio is -- while uniQure NV's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Merus NV is 64.40x versus 34.51x for uniQure NV. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    MRUS
    Merus NV
    64.40x -- $26.5M -$96.5M
    QURE
    uniQure NV
    34.51x -- $1.6M -$43.6M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Where Will Hershey Stock Be In 1 Year?
Where Will Hershey Stock Be In 1 Year?

Chocolate stocks used to be the epitome of sleepy stability,…

Where Will KNOT Stock Be In 1 Year?
Where Will KNOT Stock Be In 1 Year?

In the case of KNOT Offshore Partners (KNOP), most headlines…

Why Is Goldman Sachs Stock Up So Much?
Why Is Goldman Sachs Stock Up So Much?

Investment banking giant Goldman Sachs (NYSE:GS) has sharply outperformed the…

Stock Ideas

Buy
60
Is NVDA Stock a Buy?

Market Cap: $3.7T
P/E Ratio: 52x

Buy
62
Is MSFT Stock a Buy?

Market Cap: $3.7T
P/E Ratio: 42x

Sell
46
Is AAPL Stock a Buy?

Market Cap: $3.1T
P/E Ratio: 34x

Alerts

Buy
60
AEVA alert for Jul 2

Aeva Technologies [AEVA] is up 7.78% over the past day.

Sell
44
PRGS alert for Jul 2

Progress Software [PRGS] is down 2.94% over the past day.

Sell
46
NAIL alert for Jul 2

Direxion Daily Homebuilders & Supplies Bull 3X Shs [NAIL] is up 3.1% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock